论文部分内容阅读
柳胺苄心定(labetalol)对α及β受体具有双重阻断作用,是一种疗效迅速、可靠且副作用小的新型降压药物。药效学和药物动力学动物实验证明,柳胺苄心定对β_1、β_2和α_1受体有阻断作用,而对α_2受体则无作用。降压效应主要通过阻断α受体引起外周血管扩张所致。本药对α_1受体的阻断作用约为酚妥拉明的1/6～1/10。由于支气管平滑肌及冠脉也存在α受体,故尚有扩张支气管平滑肌和冠脉的作用。柳胺苄心定的β阻断作用表现在心率减慢、心脏指数(cardiac index,CI)减少等方面。其对心脏β受体的阻断作用约为心得
Labetalol has a dual blocking effect on α and β receptors and is a new type of antihypertensive drug with rapid, reliable and small side effect. Pharmacodynamics and Pharmacokinetics Animal experiments show that liu amine benzylbinding on β 1, β 2 and α 1 receptor block, but α 2 receptor no effect. Antihypertensive effect mainly by blocking the α receptor caused by peripheral vasodilatation. The drug on the α_1 receptor blocking effect of about phentolamine 1/6 ~ 1/10. As bronchial smooth muscle and coronary artery also exist α receptor, it is still the expansion of bronchial smooth muscle and coronary artery function. Salicylamine Benzidine β-blockade in the performance of slow heart rate, cardiac index (cardiac index, CI) reduction and so on. Its blocking effect on the heart β receptor is about experience